Skip to main content

Table 1 Demographics of the patients with cancers analyzed for microsatellite instability

From: Microsatellite instability is biased in Amsterdam II-defined Lynch-related cancer cases with family history but is rare in other cancers: a summary of 1000 analyses

Cancer type

n

Male (%)

Age

Purpose of MSI test

Smoking

Drinking

n

%

mean SD

range

genetic counseling

companion diagnostics

n

%

n

%

LS (AII)-related cancers

 Colorectum

466

283

61%

62.4 ± 12.3

25–87

127

339

302

65%

239

51%

 Endometrium

75

0

0%

57.9 ± 10.5

35–81

31

44

20

27%

14

19%

 Small intestine

15

9

60%

68.6 ± 11.1

50–82

6

9

9

60%

6

40%

 Renal pelvic/ureter

0

0

ー

ー

ー

ー

ー

ー

ー

ー

ー

Subtotal

556

292

53%

62.0 ± 12.1§1

25–87

164

392

331

60%#1

259

47%*1

LS (rB-AII)-related cancers

 Pancreas

162

86

53%

65.9 ± 9.9

30–84

29

133

76

47%

70

43%

 Biliary tract

64

40

63%

66.3 ± 9.7

38–84

1

63

33

52%

38

59%

 Stomach

36

22

61%

64.6 ± 9.7

39–81

18

18

29

81%

24

67%

 Ovary

24

0

0%

57.9 ± 13.4

27–80

3

21

5

21%

6

25%

 Brain

2

1

50%

49.0 ± 4.2

46–52

2

0

1

50%

0

0%

Subtotal

288

149

52%

65.0 ± 10.4§2

27–84

53

235

144

50%#2

138

48%*2

Non-LS-related cancers

 Uterine cervix

34

0

0%

53.9 ± 13.1

33–75

0

34

14

41%

15

44%

 Laryngopharyngus and esophagus

30

24

80%

66.7 ± 10.0

45–83

0

30

28

93%

22

73%

 Skin

27

15

56%

65.1 ± 12.7

34–87

0

27

17

63%

10

37%

 Neuroendocrine

22

16

73%

64.2 ± 9.2

47–79

0

22

16

73%

16

73%

 Thymus

10

6

60%

58.9 ± 12.8

35–72

0

10

5

50%

6

60%

 Breast

7

0

0%

51.4 ± 6.5

41–60

0

7

4

57%

2

29%

 Liver

6

4

67%

68.3 ± 7.4

60–81

0

6

4

67%

3

50%

 Others

20

13

65%

54.3 ± 18.0

13–83

5

15

13

65%

15

75%

Subtotal

156

78

50%

60.5 ± 13.4§3

13–87

5

151

101

65%#3

89

57%*3

Total

1000

519

52%

62.6 ± 12.0

13–87

222

778

576

58%

486

49%

  1. MSI microsatellite instability, SD standard deviation, LS Lynch syndrome
  2. §AII: Amsterdam II criteria, #rB: revised Bethesda guidelines. §1 + §2 vs. #3: not significant, §1 vs. §2: not significant, #1 + #2 vs. #3: P = 0.053, *1 + *2 vs. *3: P = 0.02